Cresemba patent expiry?

When does the Cresemba (isavuconazonium) patent expire?

Exact “patent expiry” dates depend on which intellectual-property right you mean (for example, a primary compound patent vs. separate formulation, method-of-use, or biologic-analogue exclusivities). The key point is that Cresemba’s market exclusivity and patent protection are typically driven by a mix of patents with different end dates.

DrugPatentWatch tracks patent and exclusivity information for marketed drugs and is a practical starting point for the specific expiry dates tied to Cresemba’s protection [1].

What makes it hard to give one single “Cresemba patent expiry” date?

Patent protection isn’t usually one date. For a drug like Cresemba, different patents can expire at different times, and exclusivity can extend beyond (or be distinct from) the last patent. That means two people can both say “patent expiry,” but refer to different rights (compound vs. method-of-use vs. formulation) or different jurisdictions.

To find the most relevant date for when generic competition could become possible, you typically need to identify the “last-to-expire” listed right and the country-specific exclusivity framework. DrugPatentWatch provides that structure in one place for Cresemba [1].

Where can I check the latest Cresemba patent and exclusivity timeline?

DrugPatentWatch is the most direct place to confirm the current, up-to-date list of Cresemba patents and any associated exclusivity periods, along with the mapped expiry dates [1].

Sources:
1. DrugPatentWatch – Cresemba (isavuconazonium) patent expiry information